Skip to main content
Journal cover image

Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

Publication ,  Journal Article
Prakash, I; Thomas, SM; Greenup, RA; Plichta, JK; Rosenberger, LH; Hyslop, T; Fayanju, OM
Published in: Breast Cancer Res Treat
April 2021

PURPOSE: Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy (NST) vs upfront surgery and whether the impact of these delays on overall survival (OS) varies with treatment sequence. METHODS: Women ≥ 18 years old with Stage I-III breast cancer were identified in the National Cancer Database (2004-2014). Multivariate linear regression stratified by treatment sequence (upfront surgery vs NST [neoadjuvant chemotherapy {NAC}, neoadjuvant endocrine therapy {NAE}, or both {NACE}]) was used to identify factors associated with TTS. Cox proportional hazards models were used to estimate the effect of TTS on overall survival (OS). RESULTS: Of 693,469 patients, 14.8% (n = 102,326) received NST (NAC n = 85,143, NAE n = 10,004, NACE n = 7179). Non-White race/ethnicity, no or government-issued insurance, more extensive surgery (i.e., mastectomy and contralateral prophylactic mastectomy vs breast-conserving surgery), and post-mastectomy reconstruction were associated with significantly longer adjusted TTS for NAC and upfront-surgery recipients, but only upfront-surgery patients had progressively worse OS with increasing TTS (> 180 vs ≤ 30 days: HR = 1.31, all p < 0.001). CONCLUSIONS: Surgery extent, race/ethnicity, and insurance were associated with TTS across treatment groups, but longer TTS was only associated with worse OS in upfront-surgery patients. Our findings can help inform surgeon-patient communication, shared decision making, care coordination, and patients' expectations throughout both NST and in the perioperative period.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

April 2021

Volume

186

Issue

2

Start / End Page

535 / 550

Location

Netherlands

Related Subject Headings

  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Mastectomy, Segmental
  • Mastectomy
  • Humans
  • Female
  • Chemotherapy, Adjuvant
  • Breast Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Prakash, I., Thomas, S. M., Greenup, R. A., Plichta, J. K., Rosenberger, L. H., Hyslop, T., & Fayanju, O. M. (2021). Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. Breast Cancer Res Treat, 186(2), 535–550. https://doi.org/10.1007/s10549-020-06012-7
Prakash, Ipshita, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Terry Hyslop, and Oluwadamilola M. Fayanju. “Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.Breast Cancer Res Treat 186, no. 2 (April 2021): 535–50. https://doi.org/10.1007/s10549-020-06012-7.
Prakash I, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Hyslop T, et al. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. Breast Cancer Res Treat. 2021 Apr;186(2):535–50.
Prakash, Ipshita, et al. “Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.Breast Cancer Res Treat, vol. 186, no. 2, Apr. 2021, pp. 535–50. Pubmed, doi:10.1007/s10549-020-06012-7.
Prakash I, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Hyslop T, Fayanju OM. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. Breast Cancer Res Treat. 2021 Apr;186(2):535–550.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

April 2021

Volume

186

Issue

2

Start / End Page

535 / 550

Location

Netherlands

Related Subject Headings

  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Mastectomy, Segmental
  • Mastectomy
  • Humans
  • Female
  • Chemotherapy, Adjuvant
  • Breast Neoplasms